| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_809af3db52a68d1016966d8f2cffad1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f28306adab6953d083eb8b65acbbad0a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 |
| filingDate |
2015-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8a3f1760a89caaf2c2422326350d02f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11068c4f8fd6e9077969204c621dd7ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3488043b759ad7e8ea36a0bdfc78bd1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ecc03edc3de2249b421af65157a9a0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db161df7664d73fb7e4d180da747b2f3 |
| publicationDate |
2016-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016042237-A1 |
| titleOfInvention |
Combined use of a trka inhibitor and an epha2 inhibitor for using in the treatment of solid cancers, and method for the prognosis of survival of a patient who has a solid cancer |
| abstract |
The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the prognosis of survival of a patient who has a solid cancer, comprising a step of detecting the expression of TrkA and EphA2 in a biological sample of the patient, the co-expression of TrkA and EphA2 being associated with a poor prognosis of survival of the patient. |
| priorityDate |
2014-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |